CN101138557A - Chlorhexidine acetate topical film-forming gel composition and application thereof - Google Patents
Chlorhexidine acetate topical film-forming gel composition and application thereof Download PDFInfo
- Publication number
- CN101138557A CN101138557A CNA200610030861XA CN200610030861A CN101138557A CN 101138557 A CN101138557 A CN 101138557A CN A200610030861X A CNA200610030861X A CN A200610030861XA CN 200610030861 A CN200610030861 A CN 200610030861A CN 101138557 A CN101138557 A CN 101138557A
- Authority
- CN
- China
- Prior art keywords
- film
- chlorhexidine acetate
- hours
- forming gel
- gel composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960002152 chlorhexidine acetate Drugs 0.000 title claims abstract description 64
- MCSINKKTEDDPNK-UHFFFAOYSA-N propyl propionate Chemical compound CCCOC(=O)CC MCSINKKTEDDPNK-UHFFFAOYSA-N 0.000 title claims abstract description 64
- 239000000203 mixture Substances 0.000 title claims abstract description 59
- 230000000699 topical effect Effects 0.000 title description 11
- 239000003431 cross linking reagent Substances 0.000 claims abstract description 25
- 239000002904 solvent Substances 0.000 claims abstract description 19
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 17
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 claims abstract description 14
- 229920000180 alkyd Polymers 0.000 claims abstract description 13
- 210000004877 mucosa Anatomy 0.000 claims abstract description 13
- 229920006395 saturated elastomer Polymers 0.000 claims abstract description 13
- 239000000126 substance Substances 0.000 claims abstract description 9
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims abstract 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 14
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 14
- 235000010447 xylitol Nutrition 0.000 claims description 14
- 239000000811 xylitol Substances 0.000 claims description 14
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 14
- 229960002675 xylitol Drugs 0.000 claims description 14
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 10
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 10
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 10
- 229930195725 Mannitol Natural products 0.000 claims description 10
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 239000000594 mannitol Substances 0.000 claims description 10
- 235000010355 mannitol Nutrition 0.000 claims description 10
- 235000010356 sorbitol Nutrition 0.000 claims description 10
- 239000000600 sorbitol Substances 0.000 claims description 10
- 235000002906 tartaric acid Nutrition 0.000 claims description 10
- 239000011975 tartaric acid Substances 0.000 claims description 10
- 229920005862 polyol Polymers 0.000 claims description 9
- 150000003077 polyols Chemical class 0.000 claims description 9
- 239000012744 reinforcing agent Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 7
- 239000001856 Ethyl cellulose Substances 0.000 claims description 5
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical group CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 5
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 5
- 229920001249 ethyl cellulose Polymers 0.000 claims description 5
- 229920002301 cellulose acetate Polymers 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 210000002200 mouth mucosa Anatomy 0.000 abstract description 14
- 150000005846 sugar alcohols Polymers 0.000 abstract description 5
- 208000035473 Communicable disease Diseases 0.000 abstract description 3
- 230000002209 hydrophobic effect Effects 0.000 abstract description 3
- 230000000717 retained effect Effects 0.000 abstract description 3
- 241001391944 Commicarpus scandens Species 0.000 abstract description 2
- 238000012423 maintenance Methods 0.000 abstract description 2
- 108010025899 gelatin film Proteins 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 238000013269 sustained drug release Methods 0.000 abstract 1
- 239000000499 gel Substances 0.000 description 74
- 210000004379 membrane Anatomy 0.000 description 36
- 239000012528 membrane Substances 0.000 description 36
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 23
- 238000012360 testing method Methods 0.000 description 22
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 18
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 18
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 14
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 14
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 14
- 239000000523 sample Substances 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 230000000844 anti-bacterial effect Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 210000004400 mucous membrane Anatomy 0.000 description 11
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 10
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 10
- 239000004327 boric acid Substances 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 9
- 229960004889 salicylic acid Drugs 0.000 description 9
- 235000015523 tannic acid Nutrition 0.000 description 9
- 229920002258 tannic acid Polymers 0.000 description 9
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 8
- 239000001263 FEMA 3042 Substances 0.000 description 8
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 8
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 8
- 229940033123 tannic acid Drugs 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 230000001070 adhesive effect Effects 0.000 description 7
- 239000002313 adhesive film Substances 0.000 description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 6
- 238000004132 cross linking Methods 0.000 description 6
- 230000007794 irritation Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000004659 sterilization and disinfection Methods 0.000 description 6
- 241000700199 Cavia porcellus Species 0.000 description 5
- 239000013068 control sample Substances 0.000 description 5
- 230000035807 sensation Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 238000005299 abrasion Methods 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 230000003628 erosive effect Effects 0.000 description 4
- 239000012374 esterification agent Substances 0.000 description 4
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- -1 biguanide compound Chemical class 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 230000007797 corrosion Effects 0.000 description 3
- 238000005260 corrosion Methods 0.000 description 3
- 238000005886 esterification reaction Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 210000004209 hair Anatomy 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical class [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- 206010020565 Hyperaemia Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000186429 Propionibacterium Species 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 241000194019 Streptococcus mutans Species 0.000 description 2
- 241000194024 Streptococcus salivarius Species 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229920013820 alkyl cellulose Polymers 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000000227 bioadhesive Substances 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- HOSGXJWQVBHGLT-UHFFFAOYSA-N 6-hydroxy-3,4-dihydro-1h-quinolin-2-one Chemical group N1C(=O)CCC2=CC(O)=CC=C21 HOSGXJWQVBHGLT-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 241000335053 Beta vulgaris Species 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000035587 bioadhesion Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- OIQPTROHQCGFEF-UHFFFAOYSA-L chembl1371409 Chemical compound [Na+].[Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=CC2=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 OIQPTROHQCGFEF-UHFFFAOYSA-L 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229940113960 edetate calcium Drugs 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 229940043351 ethyl-p-hydroxybenzoate Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 229960003639 laurocapram Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- XTUSEBKMEQERQV-UHFFFAOYSA-N propan-2-ol;hydrate Chemical compound O.CC(C)O XTUSEBKMEQERQV-UHFFFAOYSA-N 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- UJMBCXLDXJUMFB-GLCFPVLVSA-K tartrazine Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-GLCFPVLVSA-K 0.000 description 1
- 229960000943 tartrazine Drugs 0.000 description 1
- 235000012756 tartrazine Nutrition 0.000 description 1
- 239000004149 tartrazine Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开了一种醋酸氯己定局部成膜凝胶组合物,其包括如下重量百分比的组分:羟烷基纤维素0.5%~7%,酯化剂1%~10%,交联剂0.5%~5%,溶媒75%~95%和醋酸氯己定0.01%~3%;其中,该交联剂为饱和脂肪多元醇或醇酸,其化学通式为CnH2n+2-m-l(OH)m(COOH)l,该n≥m≥2,l≥0,m+l为4~8,n+l为4~8。本发明的醋酸氯己定成膜凝胶组合物用于治疗皮肤/粘膜局部感染性疾病,其涂敷在皮肤或口腔粘膜表面时会形成一层光滑、坚韧、耐磨、疏水的保护膜,该膜不易破裂、溶解和/或溶蚀,且膜具有维持时间长,药物持久释放的特点。凝胶膜可在皮肤表面有效保留8个小时以上,在口腔粘膜表面有效保留5个小时左右。The invention discloses a local film-forming gel composition of chlorhexidine acetate, which comprises the following components in percentage by weight: 0.5% to 7% of hydroxyalkyl cellulose, 1% to 10% of esterifying agent, and crosslinking agent 0.5% to 5%, solvent 75% to 95%, and chlorhexidine acetate 0.01% to 3%. Among them, the crosslinking agent is saturated fatty polyalcohol or alkyd, and its general chemical formula is C n H 2n+2- m-l (OH) m (COOH) l , n≥m≥2, l≥0, m+l is 4-8, and n+l is 4-8. The chlorhexidine acetate film-forming gel composition of the present invention is used to treat local infectious diseases of the skin/mucosa, and when it is applied on the surface of the skin or oral mucosa, it will form a smooth, tough, wear-resistant, hydrophobic protective film, The film is not easy to break, dissolve and/or erode, and the film has the characteristics of long maintenance time and sustained drug release. The gel film can be effectively retained on the skin surface for more than 8 hours, and on the oral mucosa surface for about 5 hours.
Description
技术领域 technical field
本发明涉及一种醋酸氯己定局部成膜凝胶组合物及其在治疗皮肤/粘膜局部感染性疾病中的应用。The invention relates to a local film-forming gel composition of chlorhexidine acetate and its application in treating local infectious diseases of skin/mucosa.
背景技术 Background technique
醋酸氯己定(Chlorhexidine Acetate)是一种双胍类化合物,又名醋酸洗必泰(太)、醋酸双氯苯双胍己烷,醋酸氯苯胍亭等,属于消毒杀菌防腐药。其通过改变细菌胞浆膜的通透性使细胞内容物漏出,而起到杀菌作用,对皮肤葡萄球菌属、变异链球菌、唾液链球菌、大肠埃希菌、丙酸杆菌和白念珠菌等均有抗菌活性。常见的醋酸氯己定局部用制剂有溶液剂、凝胶剂、软膏剂及喷雾剂等。但当使用上述剂型的醋酸氯己定来进行局部杀菌消毒时,由于消毒部位和周围组织的正常活动,如摩擦、体液或唾液的分泌和冲洗会使这些药剂溶解和/或溶蚀、移位、脱落,药剂与消毒部位保持时间较短,使得疗效明显降低。Chlorhexidine Acetate (Chlorhexidine Acetate) is a biguanide compound, also known as chlorhexidine acetate (tai), chlorhexidine acetate, chlorhexidine acetate, etc., belonging to disinfection and antiseptic drugs. It changes the permeability of the bacterial cytoplasmic membrane to make the cell content leak out, thereby playing a bactericidal effect, and has a bactericidal effect on Staphylococcus cutaneous, Streptococcus mutans, Streptococcus salivarius, Escherichia coli, Propionibacterium and Candida albicans, etc. Both have antibacterial activity. Common chlorhexidine acetate topical preparations include solutions, gels, ointments, and sprays. However, when chlorhexidine acetate in the above dosage form is used for local sterilization and disinfection, due to the normal activities of the disinfection site and surrounding tissues, such as friction, secretion and flushing of body fluids or saliva, these agents will be dissolved and/or eroded, displaced, If it falls off, the time between the agent and the disinfection site is relatively short, which significantly reduces the curative effect.
人们已研究了一些可在皮肤或潮湿的粘膜表面,如口腔粘膜表面形成一层黏附性膜的局部成膜凝胶组合物(成膜凝胶剂),通常又可称这类凝胶组合物为生物黏附性成膜凝胶组合物。这类载药的局部成膜凝胶组合物形成膜黏附于机体局部可提供一种持续释放药物的机构,从而提高疗效。有关这些成膜凝胶组合物的例子已被Rencher(USP5192802、5314915)、Tinnell(USP4381296和4285934)、Promerantz(USP5081158)、Epstein(USP5906814)、Tapolsky(USP6103266)公开。Some topical film-forming gel compositions (film-forming gels) that form an adhesive film on the skin or moist mucosal surfaces, such as the oral mucosa, have been studied and are commonly referred to as such gel compositions. A bioadhesive film-forming gel composition. The drug-loaded local film-forming gel composition forms a film and adheres to the body part, which can provide a mechanism for sustained release of drugs, thereby improving the curative effect. Examples of these film-forming gel compositions are disclosed by Rencher (USP5192802, 5314915), Tinnell (USP4381296 and 4285934), Promerantz (USP5081158), Epstein (USP5906814), Tapolsky (USP6103266).
其中一类局部成膜组合物通常是用水溶性材料,如西黄蓍羧、阿拉伯胶、黄原胶、海藻酸钠、羧甲基纤维素钠、卡波姆等制成,例如USP5192802公开的黏附性组合物由羧甲基纤维素钠、黄原胶、海藻酸钠等组成。但这种制剂所采用的黏附性材料大多为水溶性物质,其在患处的滞留时间很短,很容易被唾液或体液从给药部位洗脱下来。One type of topical film-forming composition is usually made of water-soluble materials, such as tragacanth, gum arabic, xanthan gum, sodium alginate, sodium carboxymethylcellulose, carbomer, etc., such as the adhesive combination disclosed in USP5192802 The product is composed of sodium carboxymethyl cellulose, xanthan gum, sodium alginate and so on. However, most of the adhesive materials used in this preparation are water-soluble substances, which have a very short residence time in the affected area and are easily eluted from the administration site by saliva or body fluids.
另一类局部成膜凝胶组合物(成膜凝胶剂)通常是用羟烷基纤维素与酯化剂反应形成羟烷基纤维素酯,再通过交联剂交联,形成可生物黏附性的成膜凝胶。由于所采用交联剂的结构和性质的不同,这类成膜凝胶组合物所形成黏附膜的物理性能如柔韧性、黏附性、抗磨损以及膜在患处的维持时间差异很大。USP5081158公开的局部成膜凝胶组合物由以下组分组成:1)羟丙基纤维素;2)无毒易挥发溶剂,如乙醇;3)酯化剂,如水杨酸和单宁酸(又称丹宁酸、鞣酸);4)交联剂,如硼酸;5)药物,如新霉素等。水杨酸和单宁酸作为酯化剂可与羟丙基纤维素上的羟基发生酯化反应形成羟丙基纤维素酯,羟丙基纤维素酯与硼酸交联后可产生以下效果:①若不加交联剂会形成二层膜,加了交联剂后可将这二层膜结合在一起;②交联后可形成较为坚韧、结实的膜。据USP5906814的报道以及我们对USP5081158实施例的研究,发现用硼酸作交联剂所形成的膜比较厚而且脆弱,当应用到患处后会被体液或唾液溶蚀而引起膜破裂、脱落,其在口腔粘膜上的滞留时间只有4~5个小时。USP5906814认为造成这种现象的原因可能与硼酸的结构性质有关,硼酸上的三个羟基可与羟丙基纤维素酯上的三个位点交联,由于硼酸上的三个羟基间距很近,所交联的三个位点只是被硼原子的空隙所分开,结果导致交联后的产物被紧紧地束缚在一起,形成了刚性、脆弱的不透明膜。而且,硼酸对很多个体的皮肤和粘膜有刺激性。Another type of topical film-forming gel composition (film-forming gel) is usually formed by reacting hydroxyalkylcellulose with an esterifying agent to form a hydroxyalkylcellulose ester, which is then crosslinked by a crosslinking agent to form a bioadhesive gel. film-forming gel. Due to the difference in the structure and properties of the cross-linking agent used, the physical properties of the adhesive film formed by this type of film-forming gel composition, such as flexibility, adhesion, abrasion resistance and the maintenance time of the film on the affected area, vary greatly. The disclosed local film-forming gel composition of USP5081158 is made up of following components: 1) hydroxypropyl cellulose; 2) nontoxic volatile solvent, as ethanol; 3) esterification agent, as salicylic acid and tannic acid (also tannic acid, tannic acid); 4) cross-linking agent, such as boric acid; 5) drugs, such as neomycin, etc. Salicylic acid and tannic acid can be used as esterification agents to react with the hydroxyl group on hydroxypropyl cellulose to form hydroxypropyl cellulose ester. After cross-linking hydroxypropyl cellulose ester with boric acid, the following effects can be produced: ① If no cross-linking agent is added, a two-layer film will be formed, and the two-layer film can be combined after adding a cross-linking agent; ② After cross-linking, a tougher and stronger film can be formed. According to the report of USP5906814 and our research on the examples of USP5081158, it is found that the film formed by using boric acid as a cross-linking agent is relatively thick and fragile. The residence time on the mucous membrane is only 4-5 hours. USP5906814 believes that the reason for this phenomenon may be related to the structural properties of boric acid. The three hydroxyl groups on the boric acid can be cross-linked with the three sites on the hydroxypropyl cellulose ester. Since the distance between the three hydroxyl groups on the boric acid is very close, The three cross-linked sites are separated only by the interstices of the boron atoms, resulting in tightly bound products after cross-linking, forming a rigid, fragile opaque film. Furthermore, boric acid is an irritant to the skin and mucous membranes of many individuals.
USP5906814公开了另一种局部成膜凝胶组合物,与USP5081158的不同之处在于将月桂酸单甘酯取代硼酸作为交联剂,其他的组分基本保持不变。当羟丙基纤维素与酯化剂反应形成羟丙基纤维素酯后,用月桂酸单甘油酯交联后能形成较为柔韧的膜,可改善USP5081158膜的脆性。但我们发现用月桂酸单甘酯作交联剂制成的局部成膜凝胶组合物,其膜的柔韧性虽有所增强,但黏附在机体组织或粘膜上的时间则比较短,如在口腔粘膜上形成的膜易被体液或唾液溶蚀/溶解,使得膜过早地破裂、脱落,以致较快消失。USP5906814 discloses another local film-forming gel composition, which differs from USP5081158 in that monoglyceryl laurate is used as a crosslinking agent instead of boric acid, and other components remain basically unchanged. After hydroxypropyl cellulose reacts with an esterifying agent to form hydroxypropyl cellulose ester, a relatively flexible film can be formed after cross-linking with monoglyceride laurate, which can improve the brittleness of USP5081158 film. However, we have found that the local film-forming gel composition made of monoglyceryl laurate as a cross-linking agent, although the flexibility of the film is enhanced, the time of adhesion to body tissues or mucous membranes is relatively short, as in The film formed on the oral mucosa is easily eroded/dissolved by body fluids or saliva, causing the film to rupture and fall off prematurely, so that it disappears quickly.
因此,如采用上述现有成膜凝胶组合物的技术制备醋酸氯己定局部成膜凝胶,会使药剂与患处的保持时间较短,影响治疗效果。Therefore, if the technology of the above-mentioned existing film-forming gel composition is used to prepare the local film-forming gel of chlorhexidine acetate, the retention time of the medicament and the affected part will be shorter, which will affect the therapeutic effect.
发明内容 Contents of the invention
本发明的目的旨在解决上述现有技术中的问题,提供一种柔韧性、黏附性、抗磨损性更好以及作用时间更长的醋酸氯己定局部成膜凝胶组合物。The object of the present invention aims to solve the problems in the above-mentioned prior art, to provide a kind of chlorhexidine acetate topical film-forming gel composition with better flexibility, adhesion, abrasion resistance and longer acting time.
本发明的上述目的通过下列技术方案来实现:本发明的醋酸氯己定局部成膜凝胶组合物包括羟烷基纤维素、酯化剂、交联剂、溶媒和醋酸氯己定;其中,该交联剂为饱和脂肪多元醇或醇酸,该脂肪多元醇或醇酸的化学通式为CnH2n+2-m-l(OH)m(COOH)l,该n≥m≥2,l≥0,m+l为4~8,n+l为4~8。The above-mentioned purpose of the present invention is achieved by the following technical solutions: chlorhexidine acetate local film-forming gel composition of the present invention comprises hydroxyalkyl cellulose, esterifying agent, linking agent, solvent and chlorhexidine acetate; Wherein, The crosslinking agent is saturated fatty polyol or alkyd, the chemical formula of the fatty polyol or alkyd is C n H 2n+2-ml (OH) m (COOH) l , the n≥m≥2,l ≥0, m+l is 4-8, n+l is 4-8.
本发明的醋酸氯己定局部成膜凝胶组合物中各组分的含量均可参照现有成膜凝胶组合物技术,如上述美国专利USP5081158和USP5906814公开的组分含量,但是本发明的醋酸氯己定局部成膜凝胶组合物可较佳地选用如下重量百分比的含量:羟烷基纤维素优选0.5%~7%,更优选2%~5%;酯化剂优选1%~10%,更优选3%~8%;交联剂优选0.5%~5%,更优选1%~3%;而醋酸氯己定则取治疗有效量,应根据具体的待治病情、接受治疗的病人的年龄和生理状况、病情严重程度、疗程长短及药用部位等因素而确定,优选0.01%~3%,更优选0.05%~1%;而溶媒可为75%~95%,实际操作时溶媒补足至100%即可,通常为85%~90%。The content of each component in the local film-forming gel composition of chlorhexidine acetate of the present invention can refer to existing film-forming gel composition technology, as the disclosed component content of above-mentioned U.S. Patent USP5081158 and USP5906814, but the present invention Chlorhexidine acetate local film-forming gel composition can preferably select the content of following percentage by weight: hydroxyalkyl cellulose preferably 0.5%~7%, more preferably 2%~5%; Esterifying agent preferably 1%~10% %, more preferably 3% to 8%; the cross-linking agent is preferably 0.5% to 5%, more preferably 1% to 3%; and chlorhexidine acetate takes a therapeutically effective amount, which should be treated according to the specific condition to be treated The age and physiological condition of the patient, the severity of the disease, the length of the course of treatment and the medicinal site are determined, preferably 0.01% to 3%, more preferably 0.05% to 1%; and the solvent can be 75% to 95%. When the solvent is added to 100%, usually 85% to 90%.
其中,本发明的醋酸氯己定局部成膜凝胶组合物还可以含有5%以下的增强剂,较佳地为0.5%~5%,更佳地为2%~3%。Wherein, the local film-forming gel composition of chlorhexidine acetate of the present invention may also contain less than 5% of enhancer, preferably 0.5%-5%, more preferably 2%-3%.
在本发明的一较佳实施例的结构式中,n+l较佳地不超过6,相应地m+l通常也不超过6,即可为C4~C6饱和脂肪多元醇,如日常所用的一些糖醇;或含有二个以上羟基,且羟基和羧基数为4~6的C4~C6饱和脂肪醇酸。In the structural formula of a preferred embodiment of the present invention, n+l is preferably no more than 6, and correspondingly m+l is usually no more than 6, that is, it can be a C 4 -C 6 saturated fatty polyol, as used in daily Some sugar alcohols; or C 4 -C 6 saturated fatty alkyd acids containing more than two hydroxyl groups, and the number of hydroxyl and carboxyl groups is 4-6 .
如上式中,n=m=l=2,例如:酒石酸,其结构式如下:As in the above formula, n=m=1=2, for example: tartaric acid, its structural formula is as follows:
酒石酸 C4H6O6 分子量为150.09Tartaric acid C 4 H 6 O 6 has a molecular weight of 150.09
本发明的另一较佳实施例的结构式中,n=m为5~6,如木糖醇、甘露醇或山梨醇,其结构式如下:In the structural formula of another preferred embodiment of the present invention, n=m is 5~6, as xylitol, mannitol or sorbitol, and its structural formula is as follows:
甘露醇 C6H14O6 分子量为182.17The molecular weight of mannitol C 6 H 14 O 6 is 182.17
山梨醇 C6H14O6 分子量为182.17The molecular weight of sorbitol C 6 H 14 O 6 is 182.17
木糖醇 C5H12O5 分子量为152.15The molecular weight of xylitol C 5 H 12 O 5 is 152.15
本发明饱和脂肪多元醇或醇酸的分子量优选在122~250,更优选150~183之间。The molecular weight of the saturated fatty polyol or alkyd of the present invention is preferably 122-250, more preferably 150-183.
本发明所述的羟烷基纤维素是指纤维素主干的支链上至少含有1个以上羟基的纤维素,如羟丙基甲基纤维素、羟丙基纤维素等,本发明优选羟丙基纤维素。The hydroxyalkyl cellulose in the present invention refers to the cellulose containing at least one hydroxyl group on the branch chain of the cellulose backbone, such as hydroxypropyl methylcellulose, hydroxypropyl cellulose, etc., and the preferred hydroxypropyl cellulose in the present invention is base cellulose.
所述的酯化剂为能与羟烷基纤维素支链上的羟基发生酯化反应生成酯的物质,如有机羧酸,优选水杨酸、单宁酸或它们的混合物,最佳地为水杨酸和单宁酸的混合物。水杨酸和单宁酸都能单独地与羟丙基纤维素发生酯化反应,其中水杨酸除了可与羟烷基纤维素发生酯化反应外,水杨酸上的羟基还可与交联剂上的羟基以氢键的形式交联。The esterification agent is a substance that can react with the hydroxyl group on the branched chain of hydroxyalkyl cellulose to generate an ester, such as an organic carboxylic acid, preferably salicylic acid, tannic acid or a mixture thereof, and is most preferably A blend of salicylic and tannic acids. Both salicylic acid and tannic acid can undergo esterification reaction with hydroxypropyl cellulose alone, in which salicylic acid can not only undergo esterification reaction with hydroxyalkyl cellulose, but also the hydroxyl group on salicylic acid can also react with cross-linked cellulose. The hydroxyl groups on the linking agent are cross-linked in the form of hydrogen bonds.
本发明所说的增强剂是指能增加膜的疏水性、耐磨性和/或黏附持久性的物质。本发明优选水不溶性的烷基纤维素,如乙基纤维素、醋酸纤维素、或它们的混合物等。The reinforcing agent mentioned in the present invention refers to a substance that can increase the hydrophobicity, abrasion resistance and/or adhesion durability of the film. In the present invention, water-insoluble alkyl celluloses are preferred, such as ethyl cellulose, cellulose acetate, or mixtures thereof.
所述的溶媒是指可溶解成膜凝胶组合物中各种组分及其酯化产物和交联产物的溶剂。本发明所用的溶媒可为可挥发掉的醇溶剂,如乙醇、异丙醇中任一种或其混合物;或醇溶剂与水;其不但能溶解和承载上述组分并有助于凝胶组合物在使用部位形成膜。The solvent refers to a solvent that can dissolve various components in the film-forming gel composition and their esterification products and cross-linking products. The solvent used in the present invention can be a volatile alcohol solvent, such as any one or a mixture thereof in ethanol, isopropanol; or alcohol solvent and water; it can not only dissolve and carry the above-mentioned components but also contribute to the gel combination The substance forms a film at the site of use.
当然,根据需要,还可在凝胶组合物中加入各种添加剂,如渗透促进剂:月桂氮卓酮(Azone)、薄荷醇、冰片、油酸、肉豆蔻酸异丙酯等;如抗氧剂:维生素E、维生素C、亚硫酸氢钠、硫代硫酸钠、叔丁基对羟基茴香醚等;螯合剂:乙二胺四乙酸二钠盐、乙二胺四乙酸钙钠盐等;抑菌剂:山梨酸及其盐、苯甲酸及其盐、对羟基苯甲酸甲酯、对羟基苯甲酸乙酯、对羟基苯甲酸丙酯、三氯叔丁醇等;色素:β-胡罗卜素、柠檬黄、亮蓝、日落黄、甜菜红等,以及药剂上其它常用的添加剂。Of course, various additives can also be added to the gel composition as required, such as penetration enhancers: laurocapram (Azone), menthol, borneol, oleic acid, isopropyl myristate, etc.; Agents: vitamin E, vitamin C, sodium bisulfite, sodium thiosulfate, tert-butyl p-hydroxyanisole, etc.; chelating agents: edetate disodium salt, edetate calcium sodium salt, etc.; Bacteria: sorbic acid and its salts, benzoic acid and its salts, methyl p-hydroxybenzoate, ethyl p-hydroxybenzoate, propyl p-hydroxybenzoate, chlorobutanol, etc.; pigment: β-carrot Sodium, tartrazine, brilliant blue, sunset yellow, beet red, etc., as well as other commonly used additives in pharmaceuticals.
总之,除交联剂由本发明的饱和脂肪多元醇或醇酸或其混合物替代外,本发明的醋酸氯己定局部成膜凝胶组合物中其余的各组分:如羟烷基纤维素、酯化剂及溶媒等的具体成分或含量均可参照现有技术。In a word, except that the cross-linking agent is replaced by the saturated fatty polyhydric alcohol or alkyd or its mixture of the present invention, the remaining components in the chlorhexidine acetate topical film-forming gel composition of the present invention: such as hydroxyalkyl cellulose, For the specific components or contents of the esterification agent and solvent, etc., reference may be made to the prior art.
本发明采用饱和脂肪多元醇或醇酸或其混合物在成膜凝胶组合物中作为交联剂,具有以下的独特优点:(1)本发明所用的交联剂分子量较小,较佳地如:木糖醇、甘露醇、山梨醇、酒石酸的分子量在150~183之间,为含有羟基、或含有羟基和羧基总数为4~8个的C4~C8碳烷,由于交联剂可交联的羟基或羧基之间基本无空间位阻,其与羟烷基纤维素酯交联后形成的氢键保持着合适的间距,使形成的膜具有较好的柔韧性。(2)本发明所用的交联剂为含有至少4个羟基的饱和脂肪多元醇,或含有至少2个羟基、且羟基与羧基总数至少为4的饱和脂肪醇酸,如酒石酸含二个羟基和二个羧基,山梨醇、甘露醇及木糖醇均含5~6个羟基,由于这些交联剂具有较多的可交联基团可将多个羟烷基纤维素酯分子有效地交联在一起,形成内部结合力更强、质量更大的网络状复合物,使得整个交联后的产物保持稳定,从而有效地避免了用硼酸或月桂酸单甘酯作为交联剂所产生的上述缺陷。(3)本发明选用作为交联剂的饱和脂肪多元醇或醇酸,如酒石酸、山梨醇、甘露醇及木糖醇等均为药用辅料或食品添加剂,生物相容性好,原料易得。The present invention adopts saturated fatty polyhydric alcohol or alkyd or its mixture in film-forming gel composition as linking agent, has following unique advantage: (1) linking agent molecular weight used in the present invention is less, preferably as : The molecular weight of xylitol, mannitol, sorbitol, tartaric acid is between 150~183, is to contain hydroxyl, or contain the C 4 ~C 8 carbon alkane that total number of hydroxyl and carboxyl is 4~8, because cross-linking agent can There is basically no steric hindrance between the cross-linked hydroxyl groups or carboxyl groups, and the hydrogen bond formed after cross-linking with the hydroxyalkyl cellulose ester maintains a suitable distance, so that the formed film has better flexibility. (2) The crosslinking agent used in the present invention is a saturated fatty polyol containing at least 4 hydroxyl groups, or a saturated fatty alkyd acid containing at least 2 hydroxyl groups and a total number of hydroxyl and carboxyl groups of 4, such as tartaric acid containing two hydroxyl groups and Two carboxyl groups, sorbitol, mannitol and xylitol all contain 5 to 6 hydroxyl groups. Since these crosslinking agents have more crosslinkable groups, multiple hydroxyalkyl cellulose ester molecules can be effectively crosslinked. Together, a network complex with stronger internal binding force and larger mass is formed, so that the entire cross-linked product remains stable, thus effectively avoiding the above-mentioned problems caused by using boric acid or monoglyceryl laurate as a cross-linking agent. defect. (3) The present invention selects the saturated fatty polyhydric alcohol or alkyd as cross-linking agent for use, as tartaric acid, sorbitol, mannitol and xylitol etc. are pharmaceutical excipients or food additives, biocompatibility is good, and raw material is easy to get .
本发明局部成膜凝胶剂的制备方法是:将醋酸氯己定和酯化剂搅拌溶解在适量(能溶解其中溶质)的溶媒中,搅拌下慢慢加入羟烷基纤维素,使之完全溶解/溶胀,继续搅拌使形成均匀的凝胶状;然后加入交联剂(需要时可加入增强剂、添加剂),继续搅拌至完全均匀,补充剩余量的溶媒,搅拌均匀,脱气,即得。The preparation method of the local film-forming gel of the present invention is: stirring and dissolving chlorhexidine acetate and an esterifying agent in an appropriate amount of solvent (which can dissolve the solute therein), slowly adding hydroxyalkyl cellulose under stirring to make it completely Dissolve/swell, continue to stir to form a uniform gel; then add a crosslinking agent (additives and additives can be added if necessary), continue to stir until completely uniform, add the remaining amount of solvent, stir evenly, and degas, that is .
由于本发明的醋酸氯己定局部成膜凝胶组合物采用了含有羟基、或羟基和羧基总数为4~8个的C4~C8碳烷作为交联剂,还可用水不溶性的烷基纤维素作为增强剂,使得其形成的膜比其它已知局部成膜组合物有更好的坚韧性、耐磨性、持久性和疏水性,其在患处的有效滞留时间更长。醋酸氯己定局部成膜凝胶剂在患处表面形成膜后,醋酸氯己定由膜内向患处表面释放,使患处局部在较长时间内一直维持较高的浓度从而获得更好的消毒杀菌效果;另外,同时由于膜的存在,起到了屏障及保护的作用,减少了外界的刺激和污染,能有效地避免或减轻外界对患处刺激引起的疼痛,同时也避免了自身的二次感染,从而促进病灶愈合。Since the chlorhexidine acetate local film-forming gel composition of the present invention has adopted the C4 ~ C8 carbon alkane that contains hydroxyl or hydroxyl and carboxyl total number is 4~8 as crosslinking agent, also can also water-insoluble alkyl Cellulose acts as a reinforcing agent so that the formed film has better toughness, abrasion resistance, durability and hydrophobicity than other known topical film-forming compositions, and its effective residence time in the affected area is longer. After the chlorhexidine acetate local film-forming gel forms a film on the surface of the affected area, chlorhexidine acetate is released from the film to the surface of the affected area, so that the affected area maintains a high concentration for a long time to obtain better disinfection and sterilization effects In addition, at the same time, due to the existence of the membrane, it plays a role of barrier and protection, reduces external stimulation and pollution, can effectively avoid or alleviate the pain caused by external stimulation to the affected area, and also avoids its own secondary infection, thereby Promote lesion healing.
本发明的另一目的是提供本发明的醋酸氯己定成膜凝胶组合物在制备用于治疗皮肤、粘膜局部感染性疾病的局部抗菌药物中的应用。醋酸氯己定是一种消毒杀菌防腐药,对皮肤葡萄球菌属、变异链球菌、唾液链球菌、大肠埃希菌、丙酸杆菌和白念珠菌等均有抗菌活性。Another object of the present invention is to provide the application of the chlorhexidine acetate film-forming gel composition of the present invention in the preparation of local antibacterial drugs for the treatment of skin and mucous membrane local infectious diseases. Chlorhexidine acetate is a disinfectant, antiseptic and antiseptic drug that has antibacterial activity against Staphylococcus cutaneous, Streptococcus mutans, Streptococcus salivarius, Escherichia coli, Propionibacterium and Candida albicans.
本发明的醋酸氯己定局部成膜凝胶组合物可采用棉拭或直接用干净的手指将制剂涂在皮肤或口腔粘膜患处,待溶媒挥发后可在患处形成一层光滑、坚韧、耐磨、黏附持久的疏水附膜,通常情况下该膜可在口腔粘膜表面有效保留5个小时左右,在皮肤表面有效保留8个小时以上。且本发明的醋酸氯己定成膜凝胶组合物对其施用局部无刺激,安全性好。The local film-forming gel composition of chlorhexidine acetate of the present invention can adopt cotton swab or directly use clean finger to apply preparation on the affected part of skin or oral mucosa, after the solvent volatilizes, a smooth, tough and wear-resistant layer can be formed on the affected part , Adhesive and durable hydrophobic film, under normal circumstances, the film can be effectively retained on the surface of the oral mucosa for about 5 hours, and effectively retained on the surface of the skin for more than 8 hours. Moreover, the chlorhexidine acetate film-forming gel composition of the present invention has no irritation to its local application and has good safety.
具体实施方式 Detailed ways
以下实施例用于描述本发明,但不作为对本发明的限制。The following examples are used to describe the present invention, but are not intended to limit the present invention.
下列实施例中的各种组分原料均为常规市售产品。其中未特殊说明的百分比均为重量百分比。The various component raw materials in the following examples are conventional commercially available products. Wherein the percentages not specified are all percentages by weight.
实施例1~16及对照实施例Embodiment 1~16 and comparative example
分别将表1中实施例1~14及对照实施例(1′表示)中的用量的醋酸氯己定(对照实施例中不加醋酸氯己定)和酯化剂搅拌溶解在可溶解量的溶媒中,搅拌下慢慢加入羟丙基纤维素,使完全溶解/溶胀后,继续搅拌使形成均匀的凝胶状;然后加入交联剂(需要时可加入增强剂),继续搅拌使完全均匀;补充剩余量的溶媒,使达到处方量,搅拌均匀,脱气,分别制得醋酸氯己定局部成膜凝胶组合物和不含醋酸氯己定的对照成膜凝胶组合物100克。The chlorhexidine acetate (do not add chlorhexidine acetate) and the esterifying agent stirring and dissolving in soluble amount respectively in embodiment 1~14 in table 1 and the chlorhexidine acetate of consumption in the comparative example (1 ' represents) In the solvent, slowly add hydroxypropyl cellulose under stirring to completely dissolve/swell, then continue to stir to form a uniform gel; then add a cross-linking agent (if necessary, add a reinforcing agent), continue to stir to make it completely uniform Supplement the solvent of remaining amount, make reach prescription quantity, stir, degassing, respectively make chlorhexidine acetate local film-forming gel composition and 100 grams of contrast film-forming gel composition not containing chlorhexidine acetate.
表1Table 1
实验结果表明醋酸氯己定局部成膜凝胶组合物外观呈透亮的黄棕色,能在机体组织上形成一层光滑、坚韧、耐磨、持久的疏水附膜。Experimental results show that the chlorhexidine acetate local film-forming gel composition has a translucent yellow-brown appearance, and can form a smooth, tough, wear-resistant and durable hydrophobic film on body tissues.
效果实施例1Effect Example 1
对实施例1的醋酸氯己定局部成膜凝胶剂进行影响因素和稳定性考察,结果表明本品在光照(4500LUX)、高温(40℃)条件下各10天的影响因素试验、加速试验(30℃、RH75%)6个月和室温留样(25℃、RH60%)6个月的稳定性考察,其性状、均匀性、药物含量、有关物质等与原始数据比较均无明显变化,结果见表2。The chlorhexidine acetate local film-forming gel of embodiment 1 is carried out influence factor and stability investigation, the result shows that this product is each 10 days influence factor test, accelerated test under light (4500LUX), high temperature (40 ℃) condition (30°C, RH75%) for 6 months and room temperature reserved samples (25°C, RH60%) for 6 months, the properties, uniformity, drug content, related substances, etc. have no significant changes compared with the original data, The results are shown in Table 2.
表2Table 2
效果实施例2Effect Example 2
取实施例2~14的醋酸氯己定局部成膜凝胶组合物、按美国专利USP5081158的实施例1方法制备的样品,简称USP Gel-A,配方中加入醋酸氯己定(配方w/w:醋酸氯己定0.5%、羟丙基纤维素2.5%、水杨酸2.5%、单宁酸7%、硼酸1%、乙醇86.5%)、按美国专利USP5906814的实施例Gel D方法制备的样品,简称USP Gel-B,用醋酸氯己定取代苯佐卡因(配方w/w:醋酸氯己定0.5%、羟丙基纤维素1.5%、水杨酸2.0%、月桂酸单甘酯5.0%、乙二胺四乙酸二钠盐0.05%、维生素E 0.1%、乙醇90.85%等)样品进行体外皮肤黏附性能、破损状况和滞留时间的比较,以上凝胶剂中均含有醋酸氯己定,后两者作为对照。Get the chlorhexidine acetate local film-forming gel composition of embodiment 2~14, the sample prepared by the embodiment 1 method of U.S. Patent USP5081158, be called for short USP Gel-A, add chlorhexidine acetate (prescription w/w) in the formula : chlorhexidine acetate 0.5%, hydroxypropyl cellulose 2.5%, salicylic acid 2.5%, tannic acid 7%, boric acid 1%, ethanol 86.5%), the sample prepared by the embodiment Gel D method of U.S. Patent USP5906814 , referred to as USP Gel-B, with chlorhexidine acetate instead of benzocaine (formula w/w: chlorhexidine acetate 0.5%, hydroxypropyl cellulose 1.5%, salicylic acid 2.0%, monoglyceryl laurate 5.0 %, EDTA disodium salt 0.05%, vitamin E 0.1%, ethanol 90.85%, etc.) samples were compared for in vitro skin adhesion performance, damage status and residence time, all of the above gels contain chlorhexidine acetate, The latter two serve as controls.
取3×4cm大小、新鲜的大鼠背部皮肤,修剪去皮肤内侧的血管和结缔组织,用生理盐水浸泡、洗涤,晾干;将内径16mm、厚0.6mm的模圈置皮肤上,分别将以上样品涂布到模圈内,用平板刮平,于室温下自然干燥成膜后,取出模圈,将该皮肤固定在载玻片上。将以上载玻片以45°角固定在溶出仪容器的底部,按中国药典溶出度测定法(第二法)操作,900mL蒸馏水、转速200rpm、温度32℃。观察载玻片上膜的情况,结果见表3。Take 3×4cm fresh back skin of rats, trim off blood vessels and connective tissue inside the skin, soak in saline, wash, and dry; The sample is coated into the mold ring, scraped with a flat plate, and dried naturally at room temperature to form a film, then the mold ring is taken out, and the skin is fixed on a glass slide. Fix the above glass slide at the bottom of the dissolution apparatus container at an angle of 45°, and operate according to the Chinese Pharmacopoeia dissolution method (second method), 900mL distilled water, 200rpm rotation speed, and 32°C temperature. Observe the situation of the film on the glass slide, the results are shown in Table 3.
表3.table 3.
以上的结果表明:USP Gel-A、USP Gel-B和本发明的醋酸氯己定局部成膜凝胶组合物均能在皮肤表面形成一层黏附膜,但USP Gel-A、USP Gel-B的膜在水中会被溶蚀、破损。本发明的醋酸氯己定局部成膜凝胶组合物形成的膜具有极强的生物黏附性和疏水性,即使在水中放置10个小时以上,膜基本保持完整并且仍紧紧黏附在粘膜上。The above results show that: USP Gel-A, USP Gel-B and the local film-forming gel composition of chlorhexidine acetate of the present invention can form a layer of adhesive film on the skin surface, but USP Gel-A, USP Gel-B The membrane will be eroded and damaged in water. The film formed by the chlorhexidine acetate local film-forming gel composition of the present invention has extremely strong bioadhesion and hydrophobicity, and even if it is placed in water for more than 10 hours, the film basically remains intact and still tightly adheres to the mucous membrane.
效果实施例3Effect Example 3
取实施例1、13制备的醋酸氯己定局部成膜凝胶组合物、上述USPGel-A、USP Gel-B的样品进行人口腔粘膜黏附性能、溶蚀状况和滞留时间的比较,后两者作为对照。Get the chlorhexidine acetate local film-forming gel composition that embodiment 1, 13 prepare, the sample of above-mentioned USPGel-A, USP Gel-B carry out the comparison of human oral mucosa adhesion property, erosion situation and residence time, latter two as control.
将20名健康的志愿者随机分成4组,每组5人,用干净纱布擦干口腔颊窝粘膜表面的水分,分别将样品以涂薄层的方式涂在已处理过的口腔粘膜上,张口正常呼吸1分钟,4个样品均能形成一层黏附膜,考察期间志愿者可自由饮水、交谈,滞留时间超过4小时者可进餐1次。观察膜的黏附性能、溶蚀状况和在粘膜上的滞留时间(以膜面积消失1/2以上计),并要求志愿者描述膜在口腔粘膜上的感觉,结果见表4。Divide 20 healthy volunteers into 4 groups at random, 5 people in each group, dry the moisture on the surface of the buccal fossa mucosa with clean gauze, apply the samples in a thin layer on the treated oral mucosa, and open the mouth After 1 minute of normal breathing, a layer of adhesive film could be formed on all 4 samples. During the investigation period, the volunteers were free to drink water and talk, and those who stayed for more than 4 hours could eat once. Observe the adhesive properties, erosion conditions and residence time on the mucosa (based on the disappearance of more than 1/2 of the film area), and ask volunteers to describe the feeling of the film on the oral mucosa. The results are shown in Table 4.
表4.Table 4.
试验结果显示,4个样品均能在口腔粘膜上形成一层黏附膜,USPGel-A所形成的膜略感紧绷,可能与该膜柔软性较差有关;USP Gel-B和醋酸氯己定成膜凝胶形成的膜均无明显异物感,但USP Gel-B的膜易被溶解,3小时后已有1/2以上的膜消失。实施例1的醋酸氯己定局部成膜凝胶组合物所形成的膜比实施例13的醋酸氯己定成膜凝胶组合物(不含增强剂)所形成的膜在粘膜表面的滞留时间长,说明实施例1的处方中加入乙基纤维素作为增强剂能有效地延长膜的滞留时间;实施例1、13的局部成膜凝胶无论在溶蚀状况和滞留时间上均明显优于其它2个对照样品。The test results showed that all four samples could form an adhesive film on the oral mucosa, and the film formed by USP Gel-A felt slightly tight, which may be related to the poor flexibility of the film; USP Gel-B and chlorhexidine acetate The film formed by the film-forming gel has no obvious foreign body sensation, but the film of USP Gel-B is easily dissolved, and more than 1/2 of the film has disappeared after 3 hours. The residence time of the film formed by the chlorhexidine acetate local film-forming gel composition of embodiment 1 than the film formed by the chlorhexidine acetate film-forming gel composition of embodiment 13 (do not contain reinforcing agent) It shows that the addition of ethyl cellulose in the prescription of Example 1 can effectively prolong the residence time of the film as a reinforcing agent; the local film-forming gels of Examples 1 and 13 are obviously better than other gels in terms of erosion conditions and residence time. 2 control samples.
效果实施例4Effect Example 4
用实施例1、13的醋酸氯己定局部成膜凝胶剂、上述USP Gel-A、USPGel-B的样品进行大鼠皮肤黏附性能、破损状况和滞留时间的比较。The chlorhexidine acetate topical film-forming gel of embodiment 1, 13, the sample of above-mentioned USP Gel-A, USPGel-B carry out the comparison of rat skin adhesion performance, damaged condition and residence time.
将16只实验大鼠,随机分成4组,每组4只,剪掉大鼠背部的毛并用剃胡刀刮尽表面的细毛,用酒精消毒,干燥后,分别将4个样品以涂薄层的方式涂在已处理过的皮肤上,面积均为9cm2,在每个区域内涂以约150mg的样品,4个样品均能在皮肤表面形成一层固体黏附膜。每隔1小时用潮湿的羊毛刷在膜的表面轻轻地来回刷5次,观察膜的黏附性能、破损状况和在皮肤上的滞留时间,结果见表5。Divide 16 experimental rats into 4 groups at random, 4 in each group, cut off the hair on the back of the rat and shave the fine hair on the surface with a razor, disinfect with alcohol, and after drying, apply a thin layer to the 4 samples respectively Apply on the treated skin in the same way, the area is 9cm 2 , apply about 150mg of samples in each area, all 4 samples can form a layer of solid adhesive film on the skin surface. Use a damp wool brush to gently brush the surface of the film back and forth 5 times every 1 hour, and observe the adhesion performance, damage and residence time of the film on the skin. The results are shown in Table 5.
表5.table 5.
试验结果显示,4个样品均能在皮肤上形成一层黏附膜。但USP Gel-B的膜易破损和脱落,5hr时膜基本消失,USP Gel-A在7hr时膜基本消失。实施例1的醋酸氯己定局部成膜凝胶组合物所形成的膜比实施例13的醋酸氯己定局部成膜凝胶组合物(不含增强剂)所形成的膜在皮肤表面的滞留时间长,说明实施例1的处方中加入乙基纤维素作为增强剂能延长膜的滞留时间;本发明实施例1、13的醋酸氯己定局部成膜凝胶组合物形成的膜无论在溶蚀状况和滞留时间上明显优于USP Gel-A及USP Gel-B两个对照样品。滞留时间的延长使得膜内的药物能持续地释放到患处,提高治疗效果,降低给药次数。The test results showed that all four samples could form an adhesive film on the skin. However, the membrane of USP Gel-B is easy to break and fall off, and the membrane basically disappears at 5 hours, and the membrane of USP Gel-A basically disappears at 7 hours. The retention of the film formed by the chlorhexidine acetate topical film-forming gel composition of Example 1 than the film formed by the chlorhexidine acetate topical film-forming gel composition of Example 13 (without enhancer) on the skin surface The time is long, shows that in the prescription of embodiment 1, adding ethyl cellulose can prolong the residence time of film as reinforcing agent; The film that the chlorhexidine acetate local film-forming gel composition of embodiment of the present invention 1,13 forms no matter in erosion The condition and retention time are significantly better than the two control samples USP Gel-A and USP Gel-B. The prolongation of the residence time enables the drug in the membrane to be continuously released to the affected area, improving the therapeutic effect and reducing the frequency of administration.
效果实施例5Effect Example 5
采用体外抑菌试验方法来验证实施例1的醋酸氯己定局部成膜凝胶剂抗菌作用。Adopt in vitro antibacterial test method to verify the antibacterial effect of the chlorhexidine acetate local film-forming gel of embodiment 1.
1.菌悬液的制备:将金黄色葡萄球菌(ATCC 6538)、大肠杆菌(8099)、绿脓杆菌(ATCC15442)培养18hr的新鲜斜面培养物用胰蛋白胨稀释液洗下并配制成试验菌悬液,供抑菌试验环试验应用。1. Preparation of bacterial suspension: Wash the fresh slant cultures of Staphylococcus aureus (ATCC 6538), Escherichia coli (8099), and Pseudomonas aeruginosa (ATCC 15442) for 18 hours with tryptone diluent and prepare the test bacterial suspension Liquid, for antibacterial test ring test application.
2.抑菌试验方法:用无菌棉拭子分别蘸取试验菌悬液分别涂抹在营养琼脂培养基平板表面,置室温下干燥5min。取一块无菌的不锈钢模圈(模圈上有5个直径均为5mm,厚0.5mm的圆洞,各圆洞中心之间均相距30mm以上)轻轻覆盖在培养基表面,将实施例1凝胶涂抹到周边4个圆洞内并用平板刮平,中间圆洞涂抹对照实施例1’。待凝胶干燥成膜后,取出模圈,将培养皿置37℃恒温烘箱培养16-18hr后,取出,用数显游标卡尺测量抑菌环的直径并记录测量数据,试验重复4次。2. Bacteriostasis test method: Dip the test bacteria suspension with a sterile cotton swab and smear it on the surface of the nutrient agar medium plate, and dry it at room temperature for 5 minutes. Get a piece of sterile stainless steel die ring (there are 5 round holes with a diameter of 5 mm and a thickness of 0.5 mm on the die ring, and the center of each round hole is more than 30 mm apart) gently covering the surface of the culture medium, and the sample of Example 1 The gel was applied to the four surrounding holes and scraped off with a flat plate, and the middle hole was smeared with Comparative Example 1'. After the gel dries and forms a film, take out the die ring, place the petri dish in a constant temperature oven at 37°C for 16-18 hours, take it out, measure the diameter of the antibacterial ring with a digital vernier caliper and record the measurement data. The test is repeated 4 times.
3.抑菌试验结果:实施例1凝胶对金黄色葡萄球菌、大肠杆菌、绿脓杆菌的平均抑菌试验结果见表6。3. Antibacterial test results: Table 6 shows the average antibacterial test results of the gel in Example 1 against Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
表6.Table 6.
实施例1凝胶对金黄色葡萄球菌、大肠杆菌、绿浓杆菌的平均抑菌环直径分别为12.77mm、13.75mm和12.46mm,均大于7mm直径,表明醋酸氯己定局部成膜凝胶剂具有较强的抑菌作用。Embodiment 1 gel is respectively 12.77mm, 13.75mm and 12.46mm to the average bacteriostatic ring diameter of Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, all greater than 7mm diameter, shows that chlorhexidine acetate local film-forming gel Has a strong antibacterial effect.
效果实施例6Effect Example 6
1、观察实施例2的醋酸氯己定局部成膜凝胶剂(试验样品)和对照实施例的成膜凝胶剂(对照样品)对豚鼠皮肤单次和多次给药后的局部刺激反应。1, observe the local irritation reaction of the chlorhexidine acetate local film-forming gel (test sample) of embodiment 2 and the film-forming gel (control sample) of contrasting embodiment to guinea pig skin single and multiple administration .
方法:取豚鼠12只,平均分成两组,分别为单次给药组和多次给药组。预先将豚鼠背部的毛修剪干净,用酒精消毒后,在豚鼠预先已标记出的两个区域内分别涂以试验样品和对照样品。单次给药组为0.3g/豚鼠/天;多次给药组为0.3g/豚鼠/天,连续7天,分别于末次给药后24hr观察涂药部位是否有红肿、充血、渗出、变性或坏死等局部刺激反应。Method: Take 12 guinea pigs and divide them into two groups evenly, single administration group and multiple administration group. The hair on the back of the guinea pig was trimmed in advance, and after being disinfected with alcohol, the test sample and the control sample were respectively applied to the two pre-marked areas of the guinea pig. The single administration group is 0.3g/guinea pig/day; the multiple administration group is 0.3g/guinea pig/day, for 7 consecutive days, observe whether there is redness, swelling, hyperemia, exudation, Local irritation such as degeneration or necrosis.
试验结果显示:施用实施例2的醋酸氯己定局部成膜凝胶剂后,单次和多次给药组的豚鼠的涂药部位均未见有红肿、充血、渗出、变性或坏死等局部刺激反应,且试验组与对照组之间无显著性差异。The test result shows: after applying the local film-forming gel of chlorhexidine acetate of embodiment 2, there is no redness, swelling, hyperemia, exudation, degeneration or necrosis etc. Local irritation response, and there was no significant difference between the test group and the control group.
2、观察实施例1的醋酸氯己定局部成膜凝胶剂(试验样品)和对照实施例中的成膜凝胶剂(对照样品)对家兔口腔粘膜单次和多次给药后的局部刺激反应。2, observe the chlorhexidine acetate local film-forming gel (test sample) of embodiment 1 and the film-forming gel (control sample) in the comparative example to rabbit oral mucosa after single and multiple administration local irritation.
方法:取家兔12只,平均分成两组,分别为单次给药组和多次给药组。在家兔口腔粘膜两侧分别涂以试验样品和对照样品,单次给药组为1.2mL/家兔/天,多次给药组为1.2mL/家兔/天,连续7天,分别于末次给药后24hr观察大体及病理变化。Method: Take 12 rabbits and divide them into two groups on average, single administration group and multiple administration group. Apply the test sample and the control sample respectively on both sides of the oral mucosa of rabbits, the single administration group is 1.2mL/rabbit/day, and the multiple administration group is 1.2mL/rabbit/day, continuously for 7 days, respectively The general and pathological changes were observed 24 hours after the last administration.
试验结果显示:单次和多次给药组的全身状况、口腔及口腔粘膜、呼吸道均未见明显的异常,且试验组与对照组之间无显著性差异;病理报告显示家兔口腔粘膜上皮均清晰,上皮内及上皮下均无特殊病变可见。试验结果表明实施例1的醋酸氯己定局部成膜凝胶剂和其对照样品对单次或多次给药的家兔口腔粘膜的大体及病理均未见明显的刺激反应。The results of the test showed that no obvious abnormalities were found in the general condition, oral cavity, oral mucosa, and respiratory tract of the single and multiple administration groups, and there was no significant difference between the experimental group and the control group; the pathological report showed that the oral mucosal epithelium of rabbits All were clear, and no special lesions were visible in the epithelium or subepithelium. The test results show that the chlorhexidine acetate local film-forming gel of Example 1 and its control sample have no obvious irritation reaction to the general and pathological aspects of the oral mucosa of rabbits administered single or multiple times.
以上试验说明本发明醋酸氯己定局部成膜凝胶剂局部应用时的安全性佳。The above test shows that the chlorhexidine acetate local film-forming gel of the present invention has good safety during local application.
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200610030861XA CN101138557B (en) | 2006-09-06 | 2006-09-06 | Chlorhexidine acetate topical film-forming gel composition and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200610030861XA CN101138557B (en) | 2006-09-06 | 2006-09-06 | Chlorhexidine acetate topical film-forming gel composition and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101138557A true CN101138557A (en) | 2008-03-12 |
CN101138557B CN101138557B (en) | 2010-07-07 |
Family
ID=39190766
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200610030861XA Expired - Fee Related CN101138557B (en) | 2006-09-06 | 2006-09-06 | Chlorhexidine acetate topical film-forming gel composition and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101138557B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108904885A (en) * | 2018-09-25 | 2018-11-30 | 清华大学深圳研究生院 | Controlled degradation Biological water haptogen and preparation method thereof and application |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5081158A (en) * | 1988-05-02 | 1992-01-14 | Zila Pharmaceuticals, Inc. | Compositions and in situ methods for forming films on body tissue |
US5906814A (en) * | 1995-12-07 | 1999-05-25 | The Andrew Jergens Company | Topical film-forming compositions |
CN1679968A (en) * | 2005-01-26 | 2005-10-12 | 赵尔飏 | Medical supersonic conductive gel |
-
2006
- 2006-09-06 CN CN200610030861XA patent/CN101138557B/en not_active Expired - Fee Related
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108904885A (en) * | 2018-09-25 | 2018-11-30 | 清华大学深圳研究生院 | Controlled degradation Biological water haptogen and preparation method thereof and application |
CN108904885B (en) * | 2018-09-25 | 2021-02-09 | 清华大学深圳研究生院 | Controllable degradable biological water condensation film and manufacturing method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN101138557B (en) | 2010-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6069394B2 (en) | Pharmaceutical composition | |
US6329343B1 (en) | Bioadhesive antibacterial wound healing composition | |
KR940011240B1 (en) | Pharmaceutical composition for forming films on body tissue | |
JPH09510468A (en) | Gel for the treatment of skin diseases and for the disinfection of its skin | |
CA2186757C (en) | Use of biopolymers for digestive tract injuries treatment | |
CN101138557A (en) | Chlorhexidine acetate topical film-forming gel composition and application thereof | |
CN101138543B (en) | Centella asiatica partial film forming gel composition and uses thereof | |
JP2001507708A (en) | Use of dichlorobenzyl alcohol for preparing formulations for topical treatment of inflammation and formulations containing dichlorobenzyl alcohol | |
CN101190177A (en) | Dexamethasone acetate topical film-forming gel composition and its application | |
CN101190178B (en) | Antiviral partial film forming gel composition | |
CN1891300B (en) | Benzocaine film-forming gel composition and use thereof | |
CN100446814C (en) | Compound econazole nitrate film-forming gel composition and its pharmaceutical application | |
CN100571679C (en) | Lidocaine hydrochloride partial film forming gel composition and the application in pharmacy thereof | |
CN100457186C (en) | Application of saturated fatty polyol or alcoholic acid as cross-linking agent in filming gel composition | |
CN101138556B (en) | Terbinafine or its salt film-forming gel composition and application thereof | |
CN101138541B (en) | Amlexanox partial film forming gel composition and uses thereof | |
CN1899292A (en) | Triamcinolone benetonide local film forming gel composition | |
RU2181583C1 (en) | Agent for treatment and prophylaxis of diseases of maxillofacial region organs | |
Abruzzo | Chitosan based hydrogels for transmucosal drug delivery | |
US20230381217A1 (en) | Liquid composition for use in the prevention or reduction of skin irritation, allergy and/or an infectious disease | |
CN102427801A (en) | Medicinal cream prepared using neomycin sulfate B cream and chitosan and preparation method thereof | |
CN117122584A (en) | Butyl boron compound oral dissolved film and preparation method thereof | |
CN101138544B (en) | Diclofenac or its salt topical film-forming gel composition and application thereof | |
Wattanaphraya et al. | Development of film-forming solutions containing Kaempferia parviflora extract for Aphthous ulcers | |
CN116603007A (en) | A kind of wound disinfection spray and its preparation method and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100707 Termination date: 20170906 |